131 related articles for article (PubMed ID: 10828317)
1. Inhibitors of tyrosine kinases in the treatment of psoriasis.
Ben-Bassat H; Klein BY
Curr Pharm Des; 2000 Jun; 6(9):933-42. PubMed ID: 10828317
[TBL] [Abstract][Full Text] [Related]
2. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy.
Ben-Bassat H
Curr Opin Investig Drugs; 2001 Nov; 2(11):1539-45. PubMed ID: 11763154
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
Powell TJ; Ben-Bassat H; Klein BY; Chen H; Shenoy N; McCollough J; Narog B; Gazit A; Harzstark Z; Chaouat M; Levitzki R; Tang C; McMahon J; Shawver L; Levitzki A
Br J Dermatol; 1999 Nov; 141(5):802-10. PubMed ID: 10583160
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase inhibitors as novel therapeutic agents.
Levitzki A
Pharmacol Ther; 1999; 82(2-3):231-9. PubMed ID: 10454200
[TBL] [Abstract][Full Text] [Related]
5. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of tyrosine kinases in the treatment of psoriasis.
Ben-Bassat H; Levitzki A
Isr Med Assoc J; 2000 Jul; 2 Suppl():69-73. PubMed ID: 10909421
[No Abstract] [Full Text] [Related]
7. Tyrosine kinase inhibition: an approach to drug development.
Levitzki A; Gazit A
Science; 1995 Mar; 267(5205):1782-8. PubMed ID: 7892601
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinases as targets for cancer therapy.
Levitzki A
Eur J Cancer; 2002 Sep; 38 Suppl 5():S11-8. PubMed ID: 12528768
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.
Ockenfels HM; Nussbaum G; Schultewolter T; Burger PM; Goos M
Arch Dermatol Res; 1995; 287(3-4):304-9. PubMed ID: 7541191
[TBL] [Abstract][Full Text] [Related]
10. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.
Levitzki A
FASEB J; 1992 Nov; 6(14):3275-82. PubMed ID: 1426765
[TBL] [Abstract][Full Text] [Related]
11. Regulation of involucrin in psoriatic epidermal keratinocytes: the roles of ERK1/2 and GSK-3β.
Chen JQ; Man XY; Li W; Zhou J; Landeck L; Cai SQ; Zheng M
Cell Biochem Biophys; 2013 Jul; 66(3):523-8. PubMed ID: 23283814
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases.
Du XL; Gao Z; Lau CP; Chiu SW; Tse HF; Baumgarten CM; Li GR
J Gen Physiol; 2004 Apr; 123(4):427-39. PubMed ID: 15024039
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells.
Wiiger MT; Prydz H
Thromb Haemost; 2004 Jul; 92(1):13-22. PubMed ID: 15213840
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities.
Nowak F; Jacquemin-Sablon A; Pierre J
Biochem Pharmacol; 1997 Feb; 53(3):287-98. PubMed ID: 9065732
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostins suppress the growth of psoriatic keratinocytes.
Ben-Bassat H; Vardi DV; Gazit A; Klaus SN; Chaouat M; Hartzstark Z; Levitzki A
Exp Dermatol; 1995 Apr; 4(2):82-8. PubMed ID: 7640880
[TBL] [Abstract][Full Text] [Related]
17. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha.
Yoshida A; Kanno H; Watabe D; Akasaka T; Sawai T
Arch Dermatol Res; 2008 Jan; 300(1):37-45. PubMed ID: 17960400
[TBL] [Abstract][Full Text] [Related]
18. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation.
Bruch-Gerharz D; Schnorr O; Suschek C; Beck KF; Pfeilschifter J; Ruzicka T; Kolb-Bachofen V
Am J Pathol; 2003 Jan; 162(1):203-11. PubMed ID: 12507903
[TBL] [Abstract][Full Text] [Related]
19. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents.
Wells G; Seaton A; Stevens MF
J Med Chem; 2000 Apr; 43(8):1550-62. PubMed ID: 10780912
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers.
Dvir A; Milner Y; Chomsky O; Gilon C; Gazit A; Levitzki A
J Cell Biol; 1991 May; 113(4):857-65. PubMed ID: 1709168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
